-
Prof. Xiaohui Zhang’s Team: International First Exploration of JAK1/2 Inhibitor Baricitinib for the Treatment of Adult Primary ITP
Prof. Xiaohui Zhang’s pioneering study marks the first international use of baricitinib for hormone-resistant/relapsed immune thrombocytopenia (ITP). This phase 2 trial with 35 adult patients achieved a 6-month response rate of 57.1% and was well-tolerated, opening new avenues for ITP treatment. The findings were presented at the European Hematology Association and published in the American…
-
Significant Clinical Research at the 2024 International Liver Cancer Association (ILCA) Annual Conference！
From October 17-19, 2024, the 18th International Liver Cancer Association (ILCA) Annual Conference, a prestigious academic event in the global liver cancer field, took place in Toronto, Canada. Liver cancer experts from around the world convened to discuss hot topics and the latest advancements in the basics and clinical aspects of liver cancer. This conference…
-
Call for Papers by November 24丨Beijing APASL 2025 Annual Meeting, Inviting Liver Disease Research Experts to Participate
This will be the largest and most prestigious academic gathering in 2025 for liver disease and related fields in the Asia-Pacific region. The conference will cover a broad range of…
-
CSCO 2024 | Dr. Jianming Guo: Combining the Latest Advances to Further Improve Surgical Treatment for Prostate Cancer in China
Surgical treatment is a crucial approach for prostate cancer, with radical prostatectomy being the gold standard. Even for intermediate and advanced prostate cancer, surgery can offer the possibility of clinical cure. For rare subtypes and complex cases, decisions often require multidisciplinary team (MDT) discussions and thorough communication with the patient. During the recent CSCO Annual…
-
CSCO 2024 | Dr. Shukui Qin: 27 Years of Advancing Cancer Treatment, A New Chapter in Liver Cancer Therapy
From September 25 to 29, 2024, the 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held in Xiamen. Themed “Patient-Centered, Shared Future,” the conference attracted tens of thousands of oncology experts and pharmaceutical…
-
Dr. Shaoming Wang’s In-depth Analysis: Global Lifetime Risk and Prevention Strategies for Gastrointestinal Cancer | CACA Integrated Esophageal Cancer
During the 2024 CACA Integrated Esophageal Cancer Academic Conference, Dr. Shaoming Wang from the Cancer Hospital Chinese Academy of Medical Sciences gave an in-depth explanation of research progress on the burden of upper gastrointestinal cancer. During the conference, Oncology Frontier had the pleasure of interviewing Professor Wang to further explore his team’s latest research findings…
-
CSCO 2024 | Dr. Zefei Jiang: Twenty Years of Mutual Achievement, From China to the World; A Preview of the Exciting 2024 CSCO Conference
From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, will be held in Xiamen. With the theme “Patient-Centered, Sharing the Future,” the conference will showcase important research advancements and…
-
Consensus from SIDP: Primary Prevention and Therapeutic Drug Monitoring (TDM) for Triazole Antifungal Drugs
Introduction: The Society of Infectious Disease Pharmacists (SIDP) presents its consensus recommendations for primary prevention and therapeutic drug monitoring (TDM) of five commonly used triazole antifungal drugs: voriconazole, posaconazole, itraconazole,…
Connecting Medical Expertise through Media